louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01266538: Inflammatory Bowel Disease(IBD)Database
Official title: Epidemiologic, Clinical, Endoscopic and Histological Database of Patients With Inflammatory Bowel Disease (IBD)
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Inflammatory Bowel Disease
Lead sponsor: Tel-Aviv Sourasky Medical Center
Sponsor class: OTHER_GOV
First posted: 2010-12-24
Enrollment: 2500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: 1. Cases: Patients diagnosed with Inflammatory Bowel Disease (IBD) attending the departement of Gastroenterology (Tel Aviv Sourasky Medical Center) for a regular follow up / treatment.
2. Controls:Family members of IBD patients, Patients with Irritable Bowel Syndrome (IBS), Fap (familial polyposis)patients after a large bowel resection, Patient performing screening endoscopy

   --------------------------------------------------------------------------------

Brief summary: This will be a comprehensive epidemiological, clinical, endoscopic and histological database for inflammatory bowel diseases patients in our medical center that will further provide clinical and basic investigations.

Detailed description: Inflammatory bowel diseases (IBD), which include Crohn's disease (CD), ulcerative colitis (UC), undefined IBD and pouchitis (in patients who required IPAA for their colitis) affects about two million people in the world. At this time there is no definitive cure and current treatment is aimed at managing the symptoms and inflammation that accompany these diseases. These diseases are predominantly chronic, and patients may experience various gastrointestinal symptoms depending on the location, nature, and extent of their disease. Both genetic and environmental factors play etiological roles. The overall goal of our research is to understand the etiology and course of these diseases in order to prevent and to manage cases more effectively. In order to do so we are aiming at building a comprehensive database that will include detailed clinical data conjoined with dedicated research information and collection of biological specimens that will target the gut epithelium immune system, the microbiota and specific genetic risk factors.

Eligibility criteria: Inclusion Criteria:

Diagnosis of IBD Regular treatment and follow up in Tel Aviv Sourasky medical center Fap (familial polyposis)patients after a large bowel resection, as controls Family members of IBD patients as controls Patients with Irritable Bowel Syndrome (IBS), as controls -

Exclusion Criteria:

pregnancy age\<18 years

-

Primary outcomes:
measure: flactuations in gastrointestinal inflammation
timeFrame: ongoing, up to 4 times a year
Secondary outcomes:
measure: development of IBD-related morbidity and complications over time
timeFrame: ongoing, up to 4 times a year
Other outcomes:
Locations:
city: Tel Aviv
country: Israel
facility: Tel Aviv Sourasky Medical Center
Study officials:
affiliation: Tel-Aviv Sourasky Medical Center
name: Iris Dotan, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06371638: Dexmedetomidine and Postoperative Cognitive Dysfunction (POCD)
Official title: Continuous Dexmedetomidine Infusion Reduces Postoperative Cognitive Dysfunction and Postoperative Pain in Patients Undergoing Laparatomy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Postoperative Cognitive Dysfunction
Postoperative Pain
Keywords: postoperative cognitive complications
dexmedetomidine
pain
hemodynamics
Lead sponsor: Udayana University
Sponsor class: OTHER
First posted: 2024-04-17
Enrollment: 112
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Postoperative cognitive dysfunction (POCD) affects all age groups and can lead to increased morbidity and more extended hospital stays. Dexmedetomidine reduces POCD by inhibiting the increase in proinflammatory cytokines IL-6 and TNF-α, and its anti-inflammatory activity contributes to its protective effect. Previous studies found that dexmedetomidine reduced POCD incidence in non-cardiac and cardiac surgery. Therefore, the goal of this study was to specifically investigate if using TCI dexmedetomidine to maintain anaesthesia in laparotomy surgeries reduces the incidence of POCD compared to inhalation anaesthesia by sevoflurane.


Eligibility criteria: Inclusion Criteria:

* Aged \>= 18 years old
* Scheduled for laparatomy surgery

Exclusion Criteria:

* history of allergies to anaesthetic drugs
* impaired consciousness
* neurocognitive disorder
* psychiatric disorder
* mental disorder
* cerebrovascular disorders
* sick sinus syndrome
* hypoalbuminemia
* massive bleeding
* liver disease
* kidney diseases.

Primary outcomes:
measure: Postoperative cognitive dysfunction (POCD)
timeFrame: 48 hours postoperative
measure: Postoperative cognitive dysfunction (POCD)
timeFrame: 30 days postoperative
Secondary outcomes:
measure: Intraoperative hemodynamics: mean arterial pressure (MAP)
timeFrame: During the course of intraoperative period.
measure: Intraoperative hemodynamics: heart rate (HR)
timeFrame: During the course of intraoperative period.
measure: Postoperative pain
timeFrame: 1 hour postoperative
measure: Postoperative pain
timeFrame: 12 hours postoperative
measure: Postoperative pain
timeFrame: 24 hours postoperative
Other outcomes:
Locations:
city: Denpasar
country: Indonesia
facility: Prof. Ngoerah General Hospital
state: Bali
Study officials:
References:
Clinical trial NCT00842738: Can Alternative Treatment Have an Impact on Cervical Dysplasia?
Official title: Can Mindfulness Meditation Limit the Progression and/or Increase the Remission of Cervical Dysplasia?
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Cervical Dysplasia
Keywords: Screening
Cervical cancer
Cervical dysplasia
Adverse psychosocial effects
Alternative treatment
Lead sponsor: University of Copenhagen
Sponsor class: OTHER
Collaborators: name: Danish Cancer Society
First posted: 2009-02-12
Enrollment: 200
Sex: FEMALE
Minimum age (years): 23
Maximum age (years): 29
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: In this study two questions will be answered:

* can mindfulness meditation help cell-changed on the cervix to disappear?
* can mindfulness meditation lower the psychological distress when women have abnormal cervical cancer screening results?

Detailed description: 200 women, who have participated in cervical cancer screening and have mild dysplasia, will be randomized into two groups; an intervention group and a control group. The intervention group will be asked to do mindfulness meditation twice a week listening to instructions from a CD. 200 additional women having normal cervical screening results will also be included in the project.

Eligibility criteria: Inclusion Criteria:

* Women aged 23-29 years
* Participated in cervical cancer screening
* Having mild dysplasia and normal screening results

Exclusion Criteria:

* Women who have previously had dysplasia

Primary outcomes:
measure: The degree of cervical dysplasia
timeFrame: 6 months after screening
Secondary outcomes:
measure: Psychosocial consequences measured with the COS-CC questionnaire
timeFrame: 1 week, 3 and 9 months after screening
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: Department and Research Unit of General Practice, Institute of Public Health
Study officials:
References:
Clinical trial NCT05214638: Development and Application of Intelligent Assessment System of Longshi Scale
Official title: Development and Application of Intelligent Assessment System of Longshi Scale
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Stroke
Disability Physical
Keywords: Stroke
Activities of Daily Living
Electronic Version
Lead sponsor: Shenzhen Second People's Hospital
Sponsor class: OTHER
First posted: 2022-01-31
Enrollment: 115
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Stroke survivors from the Department of Rehabilitation Medicine at Shenzhen Second People's Hospital are invited to participate in this study according to the inclusion and exclusion criteria

Brief summary: The purpose of this study was to verify convenience and feasibility of the novel intelligent Longshi assessment system to provide an accurate and convenient evaluation tool for stroke survivors.


Eligibility criteria: 1. Inclusion Criteria:

   1. Stroke survivors

      * age≥18 years
      * diagnosis of cerebral infraction or intracerebral hemorrhage
      * stable vital signs
      * willingness to participate in the study with informed consent
   2. Professional evaluators:

      * One to ten years of working experience
      * experience in rehabilitation scientific research or education related work for more than two years
      * association with Longshi Scale research
   3. Non-professional evaluators：

      * the family or caregiver of stroke survivors
      * ability to read and communicate
      * willingness to participate in the study with informed consent
2. Exclusion Criteria:

   1. Stroke survivors:

      * brain tumor, Parkinson's disease or active epilepsy within past three months
      * impaired cognitive functions
      * participation in any other clinical study
   2. Professional evaluators:

      * refusal to participate in the study
   3. Non-professional evaluators:

      * care for patients with serious mental health problems
      * refusal to participate in the study

Primary outcomes:
measure: Consistency of the disability degree evaluated using the electronic version and the paper version of Longshi Scale
timeFrame: Within 48 hours
Secondary outcomes:
measure: Proportion of evaluators' preference
timeFrame: Within 48 hours
measure: Time required
timeFrame: Within 48 hours
measure: Test-retest reliability of electronic version Longshi Scale
timeFrame: Within 48 hours after first evaluation
Other outcomes:
Locations:
city: Shenzhen
country: China
facility: Shenzhen Second People's Hospital
state: Guangdong
Study officials:
References:
Clinical trial NCT01377038: OASIS: Osteoarthritis Sensitivity Integration Study
Official title: Central Pain Mechanisms in Osteoarthritis: A Longitudinal Cohort
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Osteoarthritis
Chronic Pain
Keywords: Osteoarthritis
Chronic pain
Central pain
Lead sponsor: University of Michigan
Sponsor class: OTHER
First posted: 2011-06-20
Enrollment: 0
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The primary objective of this study is to evaluate the relative efficacy of a centrally-acting analgesic (duloxetine) versus a peripherally acting analgesic (topical diclofenac) for pain and associated symptom management in knee osteoarthritis. Secondary objectives include the determination of which self-report and experimental pain measures best differentiate those who respond better to duloxetine than diclofenac.

Detailed description: This is a randomized, blinded, crossover, controlled study design comparing duloxetine and topical diclofenac for osteoarthritis pain.

The study cohort will be individuals who have a confirmed diagnosis of knee osteoarthritis. Subjects will be randomized only after all entry criteria have been met. These individuals will be evaluated at baseline, and then followed longitudinally following enrollment.

Eligibility criteria: Inclusion Criteria:

* Diagnosed with knee osteoarthritis as defined by American College of Rheumatology (ACR) criteria
* Males and females age greater than 50 years at time of screening

Exclusion Criteria:

* History of chronic kidney disease or moderate to severe hepatic impairment
* History of anemia
* Allergy or intolerance of drug intervention
* Inability to participate in outcome measures

Primary outcomes:
measure: Pain
timeFrame: One month
Secondary outcomes:
Other outcomes:
Locations:
city: Ann Arbor
country: United States
facility: University of Michigan
state: Michigan
Study officials:
affiliation: University of Michigan
name: Kristine Phillips, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Murphy SL, Lyden AK, Kratz AL, Fritz H, Williams DA, Clauw DJ, Gammaitoni AR, Phillips K. Characterizing Pain Flares From the Perspective of Individuals With Symptomatic Knee Osteoarthritis. Arthritis Care Res (Hoboken). 2015 Aug;67(8):1103-11. doi: 10.1002/acr.22545.
Clinical trial NCT04473508: Erectus Nerve Block for Lumbar Spine Surgery
Official title: Erectus Nerve Block for Lumbar Spine Surgery : a Prospective Randomized Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Spine Surgery
Pain Relief
Morphine
AdverseEvent
Lead sponsor: Centre Hospitalier Universitaire de Nīmes
Sponsor class: OTHER
First posted: 2020-07-16
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: : Spine surgery induced severe postoperative pain. Several techniques as intravenous multimodal analgesia have been proposed to reduce pain relief and morphine rescue over the first postoperative days. Regional anesthesia using the erectus nerve block is a simple infiltration across lamina of the vertebra: Ultrasound-guided posterior ramus of spinal nerve block for anesthesia and analgesia in lumbar spinal surgery This study compared erector nerve block with local anesthetic vs placebo to reduce pain and morphine rescue after lumbar spine surgery. The investigators hypothesized that eructor nerve block induced a large block from L1 to L5 that induced posterior nerve roots block anesthesia. This block reduced pain after surgery.


Eligibility criteria: Inclusion Criteria:

* age\> 18years and \<80 years
* lumbar spine surgery (2-4 levels)
* posterior approach
* ASA 1-3

Exclusion Criteria:

* refusal
* age \< 18yrs
* \<50 kg and \>120 kg
* pregnant
* renal or hepatic severe desease
* ASA 4
* no French speaking
* emergency surgery
* local or systemic infection
* surgical resumption of the surgical site
* surgery involving a thoracic approach
* allergy to local anesthetics

Primary outcomes:
measure: morphine consumption (mg)
timeFrame: 24 Hours after surgery
Secondary outcomes:
measure: Adverse events
timeFrame: from surgery to 3 months
measure: pain at rest and at movement: Visual Analogic scale
timeFrame: Day 1 to Day 3, Day od hospital discharge and month 3
measure: chronic pain: DN4 questionnaire
timeFrame: Questionnaire DN4 at 3 months
measure: Length of hospital stay
timeFrame: hospital length of stay, an average of 4 days
measure: Length of stay in the post-intervention care unit
timeFrame: Day 1
measure: Patient Satisfaction: visual analogic scale
timeFrame: Day of hospital discharge, an average of day 4
measure: Patient Quality of life: EQ-5D Questionnaire
timeFrame: 3 months
Other outcomes:
Locations:
city: Nîmes
country: France
facility: CHU Nimes
state: Gard
Study officials:
affiliation: Geoffrey.avis@chu-nimes.fr
name: Geoffrey Avis, Md
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00522808: A Study of the PK, Safety and Antiviral Activity of A-831 in HCV Carriers
Official title: A Clinical Pharmacology Study to Determine the Pharmacokinetic , Safety and Tolerability Profile and Antiviral Activity of Multiple Oral Doses of A-831 in Otherwise Healthy Male Hepatitis C Carriers With Compensated Liver Disease
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
PHASE2
Conditions: Chronic Hepatitis C
Keywords: HCV
antiviral
PK
Safety
Lead sponsor: Arrow Therapeutics
Sponsor class: INDUSTRY
Collaborators: name: DDS, Dundee
name: David Mutimer, Birmingham
name: Ed Gane, ACS New Zealand
First posted: 2007-08-30
Enrollment: 36
Sex: MALE
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purposes of this study are:

* to determine the safety and tolerability of multiple doses of A-831 at various doses
* to determine how multiple doses of A-831 are distributed through the bloodstream
* to determine if A-831 reduces the amount of Hepatitis C virus in the blood


Eligibility criteria: Inclusion Criteria:

* Volunteers will be males of any race aged 18-60 years with a BMI between 18 and 32 kg/m2 at the time of the screening medical
* Volunteers who have given their written informed consent to participate in the study
* Volunteers who are willing and able to comply with the protocol and study procedures
* Volunteers who have a diagnosis of chronic hepatitis C infection and are in good health (other than history of Hepatitis C infection)

Exclusion Criteria:

* Voulnteers with concurrent medical conditions or taking concurrent medications

Primary outcomes:
measure: Safety
measure: PK
measure: Tolerability
measure: Antiviral activity
Secondary outcomes:
Other outcomes:
Locations:
city: Auckland
country: New Zealand
facility: ACS
city: Birmingham
country: United Kingdom
facility: Birmingham WTCRF
city: Dundee
country: United Kingdom
facility: DDS
Study officials:
affiliation: DDS
name: Brian Sanderson
role: PRINCIPAL_INVESTIGATOR
affiliation: WTCRF Birmingham
name: David Mutimer
role: PRINCIPAL_INVESTIGATOR
affiliation: ACS New Zealand
name: Edward Gane
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01384708: Evaluation of a Miniaturized Microscope Device for the Detection of Esophageal Squamous Cell Cancer
Official title: Evaluation of a Miniaturized Microscope Device for the Detection of Esophageal Squamous Cell Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Squamous Cell Cancer
Keywords: squamous cell cancer
squamous cell neoplasia
Lead sponsor: Anandasabapathy, Sharmila, M.D.
Sponsor class: INDIV
Collaborators: name: William Marsh Rice University
First posted: 2011-06-29
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SCREENING

Brief summary: The overall objective of this study is to determine whether high-resolution imaging of the esophagus during routine diagnostic upper endoscopy can assist clinicians in detecting and discriminating dysplastic (precancerous) areas. This high-resolution microendoscope (HRME) was developed by our collaborators at Rice University and provides \> 1000x magnified images of the esophageal mucosa. The purpose of this study is to determine whether this device can be used to enhance the diagnostic accuracy of routine endoscopic screening for squamous cell cancer of the esophagus.


Eligibility criteria: Inclusion Criteria:

* known or suspected squamous cell neoplasia
* 18 years or older

Primary outcomes:
measure: to determine whether or not tissue is neoplastic or non-neoplastic
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: Mount Sinai Medical Center
state: New York
Study officials:
References:
citation: Protano MA, Xu H, Wang G, Polydorides AD, Dawsey SM, Cui J, Xue L, Zhang F, Quang T, Pierce MC, Shin D, Schwarz RA, Bhutani MS, Lee M, Parikh N, Hur C, Xu W, Moshier E, Godbold J, Mitcham J, Hudson C, Richards-Kortum RR, Anandasabapathy S. Low-Cost High-Resolution Microendoscopy for the Detection of Esophageal Squamous Cell Neoplasia: An International Trial. Gastroenterology. 2015 Aug;149(2):321-329. doi: 10.1053/j.gastro.2015.04.055. Epub 2015 May 14.
Clinical trial NCT03870308: fMRI of Active DBS Stimulation in Epilepsy
Official title: fMRI of Active DBS Stimulation in Epilepsy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Epilepsy
Keywords: Deep Brain Stimulation
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2019-03-12
Enrollment: 6
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: Researchers are trying to incorporate a process known as Functional MRI (fMRI) scanning to reveal a pattern in brain activity during Deep Brain Stimulation (DBS), which will correlate to possible seizure freedom.


Eligibility criteria: Inclusion Criteria

* Patients selected to undergo anterior thalamic nucleus DBS for refractory epilepsy

Exclusion Criteria

* Contraindication to MRI

Primary outcomes:
measure: DBS Stimulation
timeFrame: One year
Secondary outcomes:
Other outcomes:
Locations:
city: Jacksonville
country: United States
facility: Mayo Clinic in Florida
state: Florida
Study officials:
affiliation: Mayo Clinic
name: Erik H Middlebrooks
role: PRINCIPAL_INVESTIGATOR
References: